Management of Confirmed or Suspected Streptococcus pneumoniae Meningitis

Empiric Antimicrobial Regimens

• Adults < 60 years without risk factors – Initiate ceftriaxone 2 g IV every 12 h (or cefotaxime 2 g IV every 6 h). Add vancomycin 15–20 mg/kg IV every 12 h when penicillin‑resistance is suspected (e.g., high‑prevalence regions). Target vancomycin trough 15–20 µg/mL.  1, 2, 3

• Adults ≥ 60 years or with Listeria‑risk factors – Give ceftriaxone 2 g IV every 12 h plus amoxicillin 2 g IV every 4 h to cover Listeria monocytogenes. Listeria risk factors include diabetes, immunosuppression, cancer, and corticosteroid use. Add vancomycin as above if pneumococcal resistance is suspected.  1, 2, 3

• Children > 1 month – Use ceftriaxone 50 mg/kg IV every 12 h (maximum 4 g/day) or 100 mg/kg IV once daily.  3

Targeted Therapy According to Antimicrobial Susceptibility

• Penicillin‑susceptible pneumococcus (MIC ≤ 0.06 mg/L) – Continue ceftriaxone 2 g IV q12 h (or cefotaxime 2 g IV q6 h). Alternative: benzyl‑penicillin 2.4 g IV q4 h. Typical duration: 10 days if clinical recovery by day 10, otherwise 14 days.  1

• Penicillin‑resistant but cefalosporin‑susceptible (ceftriaxone MIC ≤ 0.5 mg/L) – Continue ceftriaxone 2 g IV q12 h (or cefotaxime 2 g IV q6 h) for 14 days.  1

• Dual‑resistant strains (ceftriaxone MIC > 0.5 mg/L) – Employ triple therapy: ceftriaxone 2 g IV q12 h + vancomycin 15–20 mg/kg IV q12 h + rifampicin 600 mg IV/oral q12 h. This regimen is essential for highly resistant isolates; treatment duration is 14 days and vancomycin trough levels should be maintained at 15–20 µg/mL.  1, 2

Evidence Supporting Combination Therapy

• Animal‑model studies demonstrate synergistic bacterial clearance from cerebrospinal fluid when vancomycin is combined with ceftriaxone against ceftriaxone‑resistant pneumococci; clinical data are limited. Expert committees therefore recommend adding vancomycin or rifampicin in regions with elevated pneumococcal resistance.  2, 3

• Rifampicin should be added only when the isolate is susceptible and there is a delayed clinical or microbiologic response; monotherapy rapidly selects resistance.  4

Duration of Therapy by Pathogen

Alternative Regimens for Ceftriaxone Allergy

• Use chloramphenicol 25 mg/kg IV every 6 h.  1

All statements are based on the cited literature; where the original source provided expert consensus, the level of evidence is considered moderate (expert opinion) rather than high‑quality randomized data.

Treatment of Streptococcus pneumoniae Meningitis

Empiric Treatment Algorithm

• The UK Joint Specialist Societies guideline recommends initiating ceftriaxone 2g IV every 12 hours (or cefotaxime 2g IV every 6 hours) for adults with confirmed or suspected pneumococcal meningitis, and adding vancomycin 15-20 mg/kg IV every 12 hours plus rifampicin 600mg twice daily if penicillin or cephalosporin resistance is suspected or confirmed, for patients of all ages 5, 6, 7
• For adults <60 years, the guideline suggests ceftriaxone 2g IV every 12 hours or cefotaxime 2g IV every 6 hours as initial therapy, with an alternative option of chloramphenicol 25 mg/kg IV every 6 hours if cephalosporin allergy is present 5, 6
• For adults ≥60 years, the guideline recommends adding amoxicillin 2g IV every 4 hours to the cephalosporin regimen to cover Listeria monocytogenes, with an alternative option of chloramphenicol 25 mg/kg every 6 hours and co-trimoxazole 10-20 mg/kg (trimethoprim component) in four divided doses 5, 6, 7

Definitive Therapy After Organism Identification

• For penicillin-sensitive S. pneumoniae (MIC ≤0.06 mg/L), the guideline recommends continuing ceftriaxone 2g every 12 hours or cefotaxime 2g every 6 hours, with an alternative option of benzylpenicillin 2.4g IV every 4 hours, for a duration of 10 days if recovered by day 10, or 14 days if not recovered 5, 7
• For penicillin-resistant but cephalosporin-sensitive strains (MIC >0.06 but ceftriaxone MIC ≤0.5 mg/L), the guideline recommends continuing ceftriaxone 2g every 12 hours or cefotaxime 2g every 6 hours, for a duration of 14 days 5, 7
• For dual penicillin and cephalosporin resistance (ceftriaxone MIC >0.5 mg/L), the guideline recommends continuing ceftriaxone 2g every 12 hours or cefotaxome 2g every 6 hours, plus vancomycin 15-20 mg/kg IV every 12 hours and rifampicin 600mg IV/oral every 12 hours, for a duration of 14 days 5, 7

Monitoring Parameters

• The guideline recommends monitoring serum vancomycin trough levels, targeting 15-20 μg/mL, and assessing clinical response daily, including fever resolution, decreased neck stiffness, and improved mental status 5

Guideline for Empiric and Targeted Management of Adult Streptococcus pneumoniae Meningitis

Empiric Antimicrobial Regimen

• Initiate combination therapy with ceftriaxone 2 g IV every 12 h (or cefotaxime 2 g IV every 6 h) plus vancomycin 15–20 mg/kg IV every 12 h immediately, and add dexamethasone 10 mg IV every 6 h for 4 days; the first steroid dose should be given 15–20 minutes before or concurrently with the first antibiotic dose. 8

• In patients aged ≥ 60 years (or those with diabetes, immunosuppression, cancer, or chronic corticosteroid use), add amoxicillin 2 g IV every 4 h to the ceftriaxone‑vancomycin backbone to ensure coverage of Listeria monocytogenes. 9

• Vancomycin is required in the empiric regimen because up to 25 % of recent ICU isolates of S. pneumoniae are non‑susceptible to penicillin; the combination with a third‑generation cephalosporin provides the most reliable coverage until susceptibility data are available. 8

• Target vancomycin trough concentrations of 15–20 µg/mL using therapeutic drug monitoring to achieve adequate cerebrospinal‑fluid penetration and bactericidal activity. 8, 9

Adjunctive Dexamethasone

• Dexamethasone administered as above significantly reduces mortality (14 % vs 34 % without steroids) and decreases unfavorable neurological outcomes (26 % vs 52 %) in pneumococcal meningitis. 8

• The first dexamethasone dose must be given 10–20 minutes before or at the same time as the first antibiotic to maximize its benefit. 8

• Continue dexamethasone for 2–4 days; most adult studies support a 4‑day course of 10 mg IV every 6 h. 8

• Steroid therapy should not be withheld even when the isolate is highly resistant to penicillin and cephalosporins, because clinical benefit persists regardless of resistance patterns. 8

Definitive Therapy After Susceptibility Results

1. Penicillin‑Susceptible S. pneumoniae (MIC ≤ 0.06 mg/L)

• De‑escalate to ceftriaxone 2 g IV every 12 h alone (or cefotaxime 2 g IV every 6 h) or switch to benzylpenicillin 2.4 g IV every 4 h.
• Discontinue vancomycin and amoxicillin once susceptibility is confirmed.
• Recommended treatment duration is 10 days if the patient is clinically stable by day 10, extending to 14 days if recovery is delayed. 9

2. Penicillin‑Resistant but Ceftriaxone‑Susceptible (Ceftriaxone MIC ≤ 0.5 mg/L)

• Continue ceftriaxone 2 g IV every 12 h (or cefotaxime 2 g IV every 6 h).
• Discontinue vancomycin when the ceftriaxone MIC is ≤ 0.5 mg/L.
• Standard treatment duration is 14 days. 9

3. Dual‑Resistant S. pneumoniae (Ceftriaxone MIC > 0.5 mg/L)

• Employ triple therapy: ceftriaxone 2 g IV every 12 h + vancomycin 15–20 mg/kg IV every 12 h + rifampicin 600 mg IV or oral every 12 h.
• Rifampicin should be added only if the isolate is susceptible to avoid rapid emergence of resistance; when combined with ceftriaxone and vancomycin it provides synergistic CSF bacterial clearance.
• Treatment duration remains 14 days. 9, 8

Avoidance of Common Pitfalls

• Vancomycin monotherapy is inadequate; it must always be paired with a third‑generation cephalosporin because vancomycin alone has poor CSF penetration and insufficient bactericidal activity. 8

• Amoxicillin must not be omitted in patients ≥ 60 years until Listeria infection is definitively excluded by culture. 9

Alternative Regimens for β‑Lactam Allergy

• In patients with a documented cephalosporin allergy, substitute chloramphenicol 25 mg/kg IV every 6 h for the third‑generation cephalosporin, while continuing vancomycin to maintain gram‑positive coverage. 9